Arax Advisory Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$232K Buy
13,674
+13,120
+2,368% +$210K ﹤0.01% 2148
2026
Q1
$8.21K Buy
554
+552
+27,600% +$8.07K ﹤0.01% 2555
2025
Q4
$32 Sell
2
-646
-100% -$9.16K ﹤0.01% 3987
2025
Q3
$7.16K Buy
+648
New +$7.08K ﹤0.01% 2736

Other funds holding AUPH

Arax Advisory Partners's AUPH Position: Q2 2026 in Review

Arax Advisory Partners increased its Aurinia Pharmaceuticals (AUPH) stake by 2,368% in Q2 2026, buying an estimated $210K and bringing the position to 13,674 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #2148.

Arax Advisory Partners first reported a position in AUPH in Q3 2025 and has held it in 4 quarters since. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Arax Advisory Partners held 13,674 shares of Aurinia Pharmaceuticals worth $232K as of Q2 2026.
  • Arax Advisory Partners bought 13,120 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $210K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2148 holding.
  • Arax Advisory Partners first reported a position in Aurinia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.